Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

BACKGROUND: Surgery is a common treatment strategy for patients with neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN) and has limited efficacy. FCN-159 is a novel anti-tumorigenic drug via selective inhibition of MEK1/2. This study assesses the safety and efficacy of FCN-159 in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiaojie, Li, Wenbin, Zeng, Kang, Xu, Zhongyuan, Li, Changxing, Kang, Zhuang, Li, Shenglan, Huang, Xin, Han, Pu, Lin, Hongmei, Hui, Ai-Min, Tan, Yan, Diao, Lei, Li, Ben, Wang, Xingli, Wu, Zhuli, Lin, Xiaoxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318822/
https://www.ncbi.nlm.nih.gov/pubmed/37400844
http://dx.doi.org/10.1186/s12916-023-02927-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318822/
https://www.ncbi.nlm.nih.gov/pubmed/37400844
http://dx.doi.org/10.1186/s12916-023-02927-2

Ejemplares similares